Moban

Schizophrenia
Treatment
1 FDA approval
20 Active Studies for Moban

What is Moban

MolindoneThe Generic name of this drug
Treatment SummaryMolindone is an indole-based medication used to treat schizophrenia and other psychoses, as well as aggressive conduct disorder. It has lower than average binding strength to dopamine receptors, but has some binding affinity to cholinergic and alpha-adrenergic receptors. Some animal studies suggest that it has properties similar to the antipsychotic drug clozapine.
Mobanis the brand name
image of different drug pills on a surface
Moban Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Moban
Molindone
1974
12

Approved as Treatment by the FDA

Molindone, also known as Moban, is approved by the FDA for 1 uses such as Schizophrenia .
Schizophrenia
Helps manage Schizophrenia

Effectiveness

How Moban Affects PatientsMolindone is a drug that does not belong to the same group as phenothiazines, butyrophenones, or thioxanthenes. In animals, it has been shown to reduce movement, aggression, and overactivity caused by amphetamines, as well as the depression caused by tranquilizers.
How Moban works in the bodyWe don't know exactly how it works, but molindone is thought to stop dopamine from causing overstimulation in the brain. By blocking dopamine's effects, it can help reduce symptoms of psychotic disorders.

When to interrupt dosage

The urged dosage of Moban is contingent upon the recognized disorder. The quantity of dosage fluctuates, dependant upon the technique of delivery featured in the table beneath.
Condition
Dosage
Administration
Schizophrenia
5.0 mg, , 25.0 mg, 10.0 mg, 100.0 mg, 50.0 mg
, Oral, Tablet, Tablet - Oral

Warnings

Moban has two contraindications that should be taken into consideration, so it should not be employed when one has any of the conditions in the following table.Moban Contraindications
Condition
Risk Level
Notes
Mental Depression
Do Not Combine
Coma
Do Not Combine
There are 20 known major drug interactions with Moban.
Common Moban Drug Interactions
Drug Name
Risk Level
Description
Amisulpride
Major
Molindone may increase the antipsychotic activities of Amisulpride.
Azelastine
Major
Molindone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Deutetrabenazine
Major
The risk or severity of adverse effects can be increased when Molindone is combined with Deutetrabenazine.
Ethanol
Major
Molindone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Molindone is combined with Oliceridine.

Moban Novel Uses: Which Conditions Have a Clinical Trial Featuring Moban?

170 active trials are underway to evaluate the efficacy of Moban in managing Schizophrenia.
Condition
Clinical Trials
Trial Phases
Schizophrenia
98 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2

Moban Reviews: What are patients saying about Moban?

5Patient Review
5/3/2008
Moban for Mental Disorder with Loss of Normal Personality & Reality
Moban has been incredibly effective for me, to the point where I haven't had to be hospitalized in over a decade. The only downside is that I have to take it at night due to potential side effects.
5Patient Review
1/2/2009
Moban for Schizophrenia
My daughter has been taking Moban and Topamax for her bipolar disorder, and it has done wonders. The life-saving properties of this medication cannot be overstated.
5Patient Review
6/2/2010
Moban for Mental Disorder with Loss of Normal Personality & Reality
I'm really disappointed that this medication is no longer being manufactured. It was great for my patients who didn't want to deal with the side effects of other antipsychotics, like weight gain.
5Patient Review
7/25/2009
Moban for Schizophrenia
What are the withdrawal systems of Moban Oral?
5Patient Review
11/8/2007
Moban for Schizophrenia
4Patient Review
12/10/2009
Moban for Mental Disorder with Loss of Normal Personality & Reality
I had some involuntary mouth movements while on this medication, but overall it was pretty effective.
1Patient Review
3/2/2010
Moban for Mental Disorder with Loss of Normal Personality & Reality
Do not under any circumstances take this medicine. My mother took it for eight months and is now permanently disabled as a result. She can't eat or drink without a feeding tube and has uncontrollable movements in her head, mouth, and legs. All of this at only 63 years old; she was previously healthy too. This drug ruined her life.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about moban

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is molindone still available?

"We now have the exclusive rights to market and sell Molindone in the USA.

Epic Pharma now has the exclusive rights to sell Molindone in the USA after it was produced and discontinued by Core Pharma in 2015-2017. It is available again from Epic Pharma effective December, 2018."

Answered by AI

What is molindone used for?

"Molindone is a typical antipsychotic that is used to treat the symptoms of schizophrenia, such as disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions."

Answered by AI

What is Moban used for?

"Moban is an antipsychotic medicine that is used to treat schizophrenia. It can help to reduce the symptoms of schizophrenia, such as hallucinations, delusions, and confused thinking."

Answered by AI

Why was Moban discontinued?

"As of January 13, 2010, the drug Moban was no longer being made by its producer, Endo Pharmaceuticals, Inc. According to the U.S. Food and Drug Administration, this was because of a business decision and not because there were any safety concerns."

Answered by AI

Clinical Trials for Moban

Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Woodland International Research Group /ID# 275747 (+4 Sites)ABBVIE INC.AbbVie
Have you considered Moban clinical trials? We made a collection of clinical trials featuring Moban, we think they might fit your search criteria.Go to Trials
Have you considered Moban clinical trials? We made a collection of clinical trials featuring Moban, we think they might fit your search criteria.Go to Trials
Image of Clinical Site in Richmond, United States.

Xanomeline/Trospium for Schizophrenia

18 - 40
All Sexes
Richmond, TX
This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium in a population of 172 participants diagnosed with schizophrenia in the early phase of illness. Participants will be followed for 24 weeks with scheduled assessments conducted by centralized raters, local mental health professionals and self-assessments completed by patients. Recruitment will be based on insufficient efficacy of previous antipsychotic or due to dissatisfaction with treatment as a result of unacceptable side effects on previous antipsychotic/patient choice, with approximately 50% for each enrollment criteria. Participants who present with both insufficient efficacy and unacceptable side effects will be considered as belonging to the insufficient efficacy subgroup. Treatment and assessments will be identical for the 2 groups. Primary outcome for participants enrolled will be improvement in overall treatment satisfaction as measured by the MSQ.
Phase 4
Waitlist Available
Clinical SiteBristol-Myers Squibb
Have you considered Moban clinical trials? We made a collection of clinical trials featuring Moban, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security